Drugs / MBX 4291
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07142707 | Sep 2025 → Oct 2026 expected | obesity disorder | MBX Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-11 | MBX Biosciences | Results MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing mbxbio.com ↗
Preliminary blinded Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, demonstrate a pharmacokinetic profile supporting the potential for once-monthly dosing and competitive weight loss in the first multiple ascending dose (MAD) cohort. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-11 | MBX Biosciences | MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing mbxbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBX 4291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07142707 ↗ |
| Route | Subcutaneous | “MBX 4291 will be administered subcutaneously (SC)” NCT07142707 ↗ |